This observational cohort study included 300 participants from the Framingham Heart Study. The population comprised individuals with Alzheimer's disease, mild cognitive impairment, dementia, or who were cognitively normal. Researchers examined longitudinal brain atrophy patterns using MRI features and compared findings to normative aging patterns. The primary outcome measured longitudinal brain atrophy components using principal components analysis.
Principal component 1 (PC1) explained 75.8% of the variance. PC2 explained 13.8% of the variance, and PC3 explained 5.4% of the variance. PC1 associations were linked to worse cognition and higher plasma AD biomarkers. PC2 showed distinct associations with biomarkers and cognition compared to PC1. PC3 showed no consistent associations with the measured outcomes.
Neuropathological analysis indicated stronger associations with AD-related tau pathology in the absence of concomitant TDP43 pathology for PC1. Secondary outcomes included plasma AD biomarkers such as p-Tau181, total Tau, GFAP, NfL, A{beta}40, and A{beta}42, as well as cognitive outcomes, neuroethological measures, tau pathology, and TDP43 pathology. Safety data, including adverse events, serious adverse events, discontinuations, and tolerability, were not reported.
Key limitations regarding follow-up duration were not reported in the study data. The practice relevance supports multimodal approaches for disease characterization and risk stratification. These findings apply to community-based cohorts investigating Alzheimer's disease and related cognitive conditions.
View Original Abstract ↓
Abstract Background: Characterizing longitudinal patterns of brain atrophy that distinguish Alzheimers disease (AD) and related neurodegeneration along with normative aging remains a major challenge. We aimed to identify data-driven longitudinal brain atrophy components and evaluate their associations with plasma AD biomarkers and cognitive outcomes in a community-based cohort. Methods: We analyzed 756 MRI scans from 300 participants in the Framingham Heart Study (mean 2.52 scans per participant; range 2 to 4). Linear mixed effects models were used to identify MRI features associated with diagnostic group (cognitively normal [CN], mild cognitive impairment [MCI], and dementia). Significant features (n=211) were entered into a longitudinal multivariate decomposition framework (ANOVA Simultaneous Component Analysis with Assorted Linear functions; ALASCA) to derive principal components (PCs) capturing patterns of structural change over time. Associations between PCs and plasma AD biomarkers (p-Tau181, total Tau(tTau), glial fibrillary acidic protein [GFAP], neurofilament light chain [NfL], amyloid-{beta}40 [A{beta}40], and amyloid-{beta}42 [A{beta}42]) were evaluated using multivariable mixed-effects models adjusted for age, sex, education, and APOE {varepsilon}4 status. Cognitive measures and neuroethological measures in a subset were used to assess the functional relevance and biological associations, respectively. Results: The first three PCs explained ~95% of the variance within the modeled MRI feature (n=211) set (PC1: 75.8%, PC2: 13.8%, PC3: 5.4%). PC1 captured medial temporal atrophy involving hippocampal subfields and basolateral amygdala and was associated with worse cognition and higher plasma AD biomarkers. Neuropathological analyses showed stronger associations of PC1-related atrophy with AD-related tau pathology in the absence of concomitant TDP43 pathology. In contrast, PC2 reflected diffuse cortical gray white matter contrast alterations across association cortices and showed distinct associations with biomarkers and cognition compared to PC1, consistent with overlapping aging- and neurodegeneration-related processes. PC3 showed limited variance and no consistent associations. Conclusion: Longitudinal MRI derived components capture distinct patterns of brain structural change associated with neurodegeneration. Medial temporal trajectories are closely associated with AD and related dementia, whereas cortical alterations likely reflect mixed aging- and disease-related processes. Integration of structural MRI with plasma biomarkers provides complementary information on disease expression and heterogeneity, supporting multimodal approaches for disease characterization and risk stratification.